Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.56
Bid: 4.30
Ask: 4.80
Change: 0.14 (3.17%)
Spread: 0.50 (11.628%)
Open: 4.16
High: 4.56
Low: 4.16
Prev. Close: 4.41
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Agreement with Syngenta Crop Protection Inc.

26 Jul 2010 07:00

RNS Number : 8791P
Plant Health Care PLC
26 July 2010
 



26 July, 2010

 

Plant Health Care plc

("Plant Health Care" or "the Company")

 

PLANT HEALTH CARE ANNOUNCES LICENSING DEAL WITH SYNGENTA

Plant Health Care (AIM: PHC), a leading provider of naturally derived products to the agriculture and landscape industries,announces that it has signed a non-exclusive agreement with Syngenta Crop Protection Inc. (Syngenta), to develop and market Plant Health Care's Harpin protein as a foliar spray in combination with Syngenta's herbicide products containing glyphosate. The combined treatment will be suitable for all crops that are tolerant to glyphosate, which is applied on more than 200 million acres worldwide per year. Syngenta, the world's largest crop protection company, is a leading provider of technologies used to control weeds, pests and disease in crops which include corn (maize), soybeans, canola and cotton.

 

In trials, Harpin has been shown to significantly increase yields on a variety of crops when applied in combination with other active ingredients including glyphosate and fungicides. Syngenta, after working with various Harpin formulations, will test multiple formulations of Harpin and glyphosate with the intention of offering new combined products as crop treatment options. Financial terms of the agreement are confidential.

 

The board of Plant Health Care believes that this deal further validates the potential of the Company's Harpin technologies in another important application designed to deliver yield increases and plant health benefits.

 

"This is Plant Health Care's second landmark agreement for our harpin technology and is a further step in the commercialisation of our technology portfolio," said John Brady, CEO of Plant Health Care. "Syngenta is an excellent partner and a major industry player, with whom we will be working closely on the next stages of the harpin/glyphosate formulation development."

 

Harpin is a specific protein that activates a plant's innate ability to protect itself and enhance growth and yield. The technology offers yield improvement, the suppression of pests like nematodes and protection against damaging diseases, as well as additive plant health benefits.

 

"As a science-based company, Syngenta is always investigating new ways to help our customers with innovative technologies which help improve crop yield and plant performance," said Ken Fister, Head, Herbicide Brand Management of Syngenta Crop Protection."We believe that the Harpin technology could provide those benefits, which we look forward to sharing with growers."

 

 

About Plant Health Care plc: Plant Health Care plc ("PHC") is a leading provider of naturally derived products for plants and soil. Established in 1995 in Pittsburgh (Pennsylvania) in the United States, PHC currently has approximately 90 employees and has operations in the United States, Mexico, the United Kingdom, Spain, and the Netherlands. The Company's ordinary shares have been quoted on the Alternative Investment Market ("AIM") of the London Stock Exchange since July 2004 and listed on the Official List of the Channel Islands Stock Exchange ("CISX") in February 2010 (ticker symbol/ mnemonic: PHC).

 

PHC's products are aimed at the agriculture and landscape industries and are environmentally beneficial. Through the commercialisation of these products, PHC is capitalising on current long-term trends toward natural systems and biological products for plant care and soil and water management. Further information is available at: www.planthealthcare.com.

 

 

- ENDS -

 

 

For further information, please contact:

 

Plant Health Care plc

John Brady, Chief Executive Officer

Tel: +1-603-525-3702

jabrady@planthealthcare.com

 

Evolution Securities

Tavistock Communications

Tim Worlledge / Tim Redfern

Jeremy Carey/Matt Ridsdale

Tel: +44-20-7071-4300

Tel: +44-20-7920-3150

tim.worlledge@evosecuties.com

tim.redfern@evosecuties.com

jcarey@tavistock.co.uk

mridsdale@tavistock.co.uk

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRUVOURRAABUAR
Date   Source Headline
8th May 20247:00 amRNSTrading Update
22nd Apr 20247:00 amRNSApproval of Harpinαβ in Belgium
16th Apr 20247:00 amRNSPlant Health Care--China Distribution with AMVAC
4th Apr 20247:00 amRNSApproval of PHC68949 in Mexico
4th Mar 20241:55 pmRNSHolding(s) in Company
24th Jan 20244:27 pmRNSHolding(s) in Company
2nd Jan 20247:00 amRNSBrazil approves TEIKKOâ„¢
20th Dec 20237:00 amRNSBoard Changes and Grant of Options
19th Dec 20233:34 pmRNSHolding(s) in Company
30th Nov 20231:45 pmRNSHolding(s) in Company
28th Nov 20233:16 pmRNSHolding(s) in Company
27th Nov 20234:03 pmRNSHolding(s) in Company
27th Nov 20231:27 pmRNSHolding(s) in Company
24th Nov 20234:19 pmRNSDirector/PDMR Shareholding
24th Nov 202310:57 amRNSDirector/PDMR Shareholding
23rd Nov 20232:31 pmRNSHolding(s) in Company
22nd Nov 20237:00 amRNSTrading Update
31st Oct 20237:00 amRNSChange of Adviser
20th Oct 20237:00 amRNSHolding(s) in Company
3rd Oct 20236:28 pmRNSPlant Health Care PREtec Product with Agrii UK
28th Sep 20237:00 amRNSNew PREtec Products Announced
27th Sep 20237:00 amRNSUnaudited Interim Results
25th Sep 20237:00 amRNSPREtec Products Submitted for Regulatory Approval
31st Aug 20237:00 amRNSNotice of Results & Investor Presentation
18th Aug 20237:00 amRNSNew Product Regulatory Approval In Brazil
1st Aug 20237:00 amRNSApproval for Sale of Harpin aß Granted in Poland
24th Jul 20237:00 amRNSGrant of Options
12th Jul 202312:27 pmRNSHolding(s) in Company
30th Jun 20235:07 pmRNSNotification of Major Holdings
28th Jun 202312:29 pmRNSHolding(s) in Company
27th Jun 20234:08 pmRNSHolding(s) in Company
27th Jun 20231:08 pmRNSDirector Shareholding
23rd Jun 20237:00 amRNSResult of Fundraising
22nd Jun 20234:35 pmRNSFundraising to raise up to US$3.6 million
14th Jun 20237:00 amRNSWilbur Ellis Agreement
13th Jun 20231:43 pmRNSResult of AGM
30th May 20237:00 amRNSHolding(s) in Company
24th May 20231:12 pmRNSHolding(s) in Company
19th May 20235:55 pmRNSPublication of Annual Report and Notice of AGM
18th May 20237:00 amRNSResult of Consultation
9th May 20237:00 amRNSPHC68949 granted first stage of approval in Brazil
2nd May 20237:10 amRNSResults for the year ended 31 December 2022
12th Apr 20232:33 pmRNSNotice of Results
5th Apr 20235:29 pmRNSHolding(s) in Company
8th Mar 20232:45 pmRNSExercise of Options
2nd Mar 20237:00 amRNSBiofungicide PHC279 Approved by US EPA
1st Mar 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Statement
30th Jan 202312:08 pmRNSSignificant Shareholder
18th Jan 20237:00 amRNSBoard Appointments

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.